|
|
International.
KLab started its global operations in regulated and
non-regulated markets for its APIs and Pharma formulations.
KLab has presence in 22 countries having registered more
than 150 products and more than 700 products are under
registration.
Regulated Markets (USA, EUROPE)
KLab is under negotiation of
outlicensing its Patented Products based
on NDDS, Nanotechnology, Dendrimers and Chiral Chemistry.
Non-Regulated Market (SOUTH
EAST, ASIA, AFRICA, LATIN
AMERICA, CIS ETC)
WHO-GMP Approved manufacturing facilities for Oncology,
General
tablets and cephalosporin.
Presently, KLab has operations in Nigeria, Ethiopia,
Kenya, Ghana, Zambia, Mozambique, Ivory Coast, Haiti,
Dominican Republic, Trinidad & Tobago, Iraq, Georgia,
Guatemala, Honduras, Myanmar, Thailand, Philippines, Hong
Kong, Cambodia, Vietnam, Sri Lanka, Maldives.
KLab expects to have its presence in Costa Rica, Ecuador,
Chile, Venezuela, Bolivia, Uganda, Tanzania, Yemen, Oman,
Jordan, Syria, Cameroon, Benin, South Africa, Pakistan,
Bhutan, Indonesia and Malaysia in near future, wherein
number of products are due for registration.
|
|
WHO-GMP
Approved manufacturing facilities
|
 |
|
WHO-GMP Approved manufacturing facilities for Oncology,
General tablets and cephalosporin.
|
| |
|
Markets
|
 |
|
Regulated Markets
(USA, EUROPE)
Non-Regulated
(SOUTH EAST, ASIA, AFRICA, LATIN
AMERICA, CIS ETC)
|
| |
|